Clusterin and complement activation in exfoliation glaucoma

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 4, 2014, Pages 2491-2499

  Doudevski, Ivo ^a   Rostagno, Agueda ^a   Cowman, Mary ^b   Liebmann, Jeffrey ^c   Ritch, Robert ^c,d   Ghiso, Jorge ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b POLYTECHNIC UNIVERSITY   (United States)

^c NEW YORK EYE AND EAR INFIRMARY   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Complement system; Exfoliation syndrome; Extracellular chaperones; Protein misfolding disorders

Indexed keywords

CLUSTERIN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C9; FIBRILLIN 1; VITRONECTIN;

ADULT; AGED; ANTERIOR LENS CAPSULE; AQUEOUS HUMOR; ARTICLE; ATOMIC FORCE MICROSCOPY; BIOACCUMULATION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PSEUDOEXFOLIATION; WESTERN BLOTTING;

COMPLEMENT SYSTEM; EXFOLIATION SYNDROME; EXTRACELLULAR CHAPERONES; PROTEIN MISFOLDING DISORDERS;

AQUEOUS HUMOR; CLUSTERIN; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXFOLIATION SYNDROME; EXTRACELLULAR MATRIX; HUMANS; LENS CAPSULE, CRYSTALLINE; MOLECULAR CHAPERONES;

EID: 84898848126     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-12941     Document Type: Article

References (55)

1. Ritch R, Schlotzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol. 2001;45:265-315.
2. Ritch R. Exfoliation syndrome: the most common identifiable cause of open-angle glaucoma. J Glaucoma. 1994;3:176-178.
3. Ritch R, Schlötzer-Schrehardt U, Konstas AG. Why is glaucoma associated with exfoliation syndrome? Progr Ret Eye Res. 2003;22:253-275.
4. Schlötzer-Schrehardt U, Naumann GO. Ocular and systemic pseudoexfoliation syndrome. Am J Ophthalmol. 2006;141: 921-937.
5. Ovodenko B, Rostagno A, Neubert TA, et al. Proteomic analysis of exfoliation deposits. Invest Ophthalmol Vis Sci. 2007;48: 1447-1457.
6. Schlötzer-Schrehardt U. Molecular pathology of pseudoexfoliation syndrome/glaucoma-new insights from LOXL1 gene associations. Exp Eye Res. 2009;88:776-785.
7. Burdon KP, Sharma S, Hewitt AW, et al. Genetic analysis of the clusterin gene in pseudoexfoliation syndrome. Mol Vis. 2008; 14:1727-1736.
8. Krumbiegel M, Pasutto F, Mardin CY, et al. Exploring functional candidate genes for genetic association in german patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma. Invest Ophthalmol Vis Sci. 2009;50:2796-2801.
9. Schlotzer-Schrehardt U, Zenkel M, Kuchle M, Sakai LY, Nauman GO. The role of transforming growth factor-b1 and its latent form binding protein in pseudoexfoliation syndrome. Exp Eye Res. 2001;73:765-780.
10. Ten VS, Yao J, Ratner V, et al. Complement component c1q mediates mitochondria-driven oxidative stress in neonatal hypoxic-ischemic brain injury. J Neurosci. 2010;30:2077-2087.
11. Clarkson AN, Sutherland BA, Appleton I. The biology and pathology of hypoxia-ischemia: an update. Arch Immunol Ther Exp. 2005;53:213-225.
12. Zenkel M, Krysta A, Pasutto F, Juenemann A, Kruse FE, Schlotzer-Schrehardt U. Regulation of lysyl oxidase-like 1 (LOXL1) and elastin-related genes by pathogenic factors associated with peudoexfoliation syndrome. Invest Ophthalmol Vis Sci. 2011;52:8488-8495.
13. Gonzalez P, Epstein DL, Borras T. Genes upregulated in the human trabecular meshwork in response to elevated intraocular pressure. Invest Ophthalmol Vis Sci. 2000;41:352-361.
14. Chen KH, Wu CC, Roy S, Lee SM, Liu JH. Increased interleukin-6 in aqueous humor of neovascular glaucoma. Invest Ophthalmol Vis Sci. 1999;40:2627-2632.
15. Wang N, Chintala SK, Fini ME, Schuman JS. Activation of a tissuespecific stress response in the aqueous outflow pathway of the eye defines the glaucoma disease phenotype. Nat Med. 2001;7:304-309.
16. Zenkel M, Kruse FE, Junemann A, Naumann GO, Schlotzer-Schrehardt U. Clusterin deficiency in eyes with pseudoexfoliation syndrome may be implicated in the aggregation and deposition of pseudoexfoliative material. Invest Ophthalmol Vis Sci. 2006;47:1982-1990.
17. Calero M, Rostagno A, Frangione B, Ghiso J. Clusterin and Alzheimer's disease. Subcell Biochem. 2005;38:273-298.
18. Calero M, Rostagno A, Matsubara E, Ziokovic B, Frangione B, Ghiso J. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc Res Tech. 2000;50:305-315.
19. Nishida K, Kawasaki S, Adachi W, Kinoshita S. Apolipoprotein J expression in human ocular surface epithelium. Invest Ophthalmol Vis Sci. 1996;37:2285-2292.
20. Nishida K, Adachi W, Shimizu-Matsumoto A, et al. A gene expression profile of human corneal epithelium and the isolation of human keratin 12 cDNA. Invest Ophthalmol Vis Sci. 1996;37:1800-1809.
21. Dota A, Nishida K, Quantock AJ, Kinoshita S. Clusterin in human corneal endothelium and aqueous humor. Exp Eye Res. 1999;69:705-708.
22. Reeder DJ, Stuart WD, Witte DP, Brown TL, Harmony JAK. Local synthesis of apolipoprotein J in the eye. Exp Eye Res. 1995;60:495-504.
23. Ritch R. The management of exfoliative glaucoma. In: Nucc C, Ceruli L, Osborne IN, Bagetta G, eds. Glaucoma: An Open Window to Neurodegeneration and Neuroprotection. New York, NY: Elsevier, Inc.; 2008:211-224.
24. Pountney DL, Lowe R, Quilty M, Vickers JC, Voelcker NH, Gai WP. Annular alpha-synuclein species from purified multiple system atrophy inclusions. J Neurochem. 2004;90:502-512.
25. Creasey R, Sharma S, Craig JE, et al. Detecting protein aggregates on untreated human tissue samples by atomic force microscopy recognition imaging. Biophys J. 2010;99: 1660-1667.
26. Fossati S, Cam J, Meyerson J, et al. Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloid-b variants in cells composing the cerebral vessel walls. Faseb J. 2010;24:229-241.
27. Rostagno A, Revesz T, Lashley T, et al. Complement activation in chromosome 13 dementias: similarities with Alzheimer's disease. J Biol Chem. 2003;277:49782-49790.
28. Radmacher M, Tillamnn RW, Fritz M, Gaub HE. From molecules to cells: imaging soft samples with the atomic force microscope. Science. 1992;257:1900-1905.
29. Cursiefen C, Hammer T, Küchle M, Naumann GO, Schlötzer-Schrehardt U. Pseudoexfoliation syndrome in eyes with ischemic central retinal vein occlusion. A histopathologic and electron microscopic study. Acta Ophthalmol Scand. 2001;79:476-478.
30. Hammer T, Schlötzer-Schrehardt U, Naumann GO. Unilateral or asymmetric pseudoexfoliation syndrome? An ultrastructural study. Arch Ophthalmol. 2001;119:1023-1031.
31. Conway RM, Schlotzer-Schrehardt U, Kuchle M, Naumann GO. Pseudoexfoliation syndrome: pathological manifestations of relevance to intraocular surgery. Clin Exp Ophthalmol. 2004; 32:199-210.
32. Milis L, Morris C, Sheehan MC, Charlesworth JA, Pussell BA. Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9. Clin Exp Immunol. 1993;92:114-119.
33. Tschopp J, French LE. Clusterin: modulation of complement function. Clin Exp Immunol. 1994;97:11-14.
34. Wilson MR, Easterbrook-Smith SB. Clusterin is a secreted mammalian chaperone. Trends Biochem Sci. 2000;25:95-98.
35. Nishida K, Quantock AJ, Dota A, Choi-Miura NH, Kinoshita S. Apolipoproteins J and E co-localize with amyloid in gelatinous drop-like and lattice type I corneal dystrophies. Br J Ophthalmol. 1999;83:1178-1182.
36. Kishore U, Reid KB. C1q: structure, function, and receptors. Immunopharmacology. 2000;49:159-170.
37. Gaboriaud C, Thielens NM, Gregory LA, Rossi V, Fontecilla-Camps JC, Arlaud GJ. Structure and activation of the C1 complex of complement: unraveling the puzzle. Trends Immunol. 2004;25:368-373.
38. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res. 2001;73:887-896.
39. Johnson LV, Forest DL, Banna CD, et al. Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration. Proc New York Acad Sci U S A. 2011;108:18277-18282.
40. Ding QJ, Cook AC, Dumitrescu AV, Kuehn MH. Lack of immunoglobulins does not prevent C1q binding to RGC and does not alter the progression of experimental glaucoma. Invest Ophthalmol Vis Sci. 2012;53:6370-6377.
41. Morgan BP. The complement system: an overview. In: Morgan BP, ed. Complement Methods and Protocols. Clifton, NJ: Humana Press; 2000:1-13.
42. McDonald JF, Nelsestuen GL. Potent inhibition of terminal complement assembly by clusterin: characterization of its impact on C9 polymerization. Biochemistry. 1997;36:7464-7473.
43. Tschopp J, Chonn A, Hertig S, French LE. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8b, and the b domain of C9. J Immunol. 1993;151: 2159-2165.
44. Morgan BP. Regulation of the complement membrane attack pathway. Crit Rev Immunol. 1999;19:173-198.
45. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383-421.
46. Rostagno A, Tomidokoro Y, Lashley T, et al. Chromosome 13 dementias. Cell Mol Life Sci. 2005;62:1814-1825.
47. Bora NS, Jha P, Bora PS. The role of complement in ocular pathology. Semin Immunopathol. 2008;30:85-95.
48. Willcox MD, Morris CA, Thakur A, Sack RA, Wickson J, Boey W. Complement and complement regulatory proteins in human tears. Invest Ophthalmol Vis Sci. 1997;38:1-8.
49. Mondino BJ, Sidikaro Y, Sumner H. Anaphylatoxin levels in human vitreous humor. Invest Ophthalmol Vis Sci. 1988;29: 1195-1198.
50. Mondino BJ, Sumner H. Anaphylotoxin levels in human aqueous humor. Invest Ophthalmol Vis Sci. 1986;27:1288-1292.
51. Zenkel M, Lewczuk P, Jünemann A, Kruse FE, Naumann GO, Schlötzer-Schrehardt U. Proinflammatory cytokines are involved in the initiation of the abnormal matrix process in pseudoexfoliation syndrome/glaucoma. Am J Pathol. 2010; 176:2868-2879.
52. Rosen AM, Stevens B. The role of the classical complement cascade in synapse loss during development and glaucoma. Adv Exp Med Biol. 2010;703:75-93.
53. Ren L, Danias J. A role for complement in glaucoma. Adv Exp Med Biol. 2010;703:95-104.
54. Kuehn MH, Kim CY, Ostojic J, et al. Retinal synthesis and deposition of complement components induced by ocular hypertension. Exp Eye Res. 2006;83:620-628.
55. Howel GR, Macalinao DG, Sousa GL, et al. Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma. J Clin Inv. 2011;121: 1429-1444.